Route of administration: Subcutaneous

6 trials

Conditions

Health Condition 1: D66- Hereditary factor VIII deficiencyHealth Condition 1: I21- Acute myocardial infarctionHealth Condition 1: M810- Age-related osteoporosis without current pathological fracture

Phase 1

A study of teriparatide injection in healthy human volunteers

Active, not recruitingCTRI/2020/10/028627

Intas Pharmaceuticals Limited

Target: 105Updated: 2021-11-24

A STUDY OF FILGRASTIM INJECTIONS IN HUMANS

Active, not recruitingCTRI/2021/03/031763

Intas Pharmaceuticals Ltd

Target: 60Updated: 2021-11-24

Phase 3

A Phase III clinical trial of Teriparatide in postmenopausal women with osteoporosis

Active, not recruitingCTRI/2021/04/032769

Intas Pharmaceuticals LtdHealth Condition 1: M810- Age-related osteoporosis without current pathological fracture

Target: 198Updated: 2023-09-18

A research study looking at long-term treatment with Mim8 in people with haemophilia A

Active, not recruitingCTRI/2024/02/062683

Novo Nordisk India Private LimitedHealth Condition 1: D66- Hereditary factor VIII deficiency

Target: 425Updated: 2026-06-22

ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people with a heart attack

Active, not recruitingCTRI/2024/06/068283

Novo Nordisk A SHealth Condition 1: I21- Acute myocardial infarction

Target: 10000Updated: 2026-09-14

Unknown Phase

Bioequivalence study of Insulin 30/70

Active, not recruitingCTRI/2025/05/087610

Virchow Biotech Private Limited

Target: 40Updated: 2025-06-24

Related Papers

Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.